KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 112 filers reported holding KEROS THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,037,460 | -21.6% | 32,543 | -1.2% | 0.00% | 0.0% |
| Q2 2023 | $1,324,051 | +110329.6% | 32,953 | +17.3% | 0.00% | 0.0% |
| Q1 2023 | $1,199 | -5.4% | 28,091 | +6.5% | 0.00% | -50.0% |
| Q4 2022 | $1,267 | -99.9% | 26,384 | +13.0% | 0.00% | +100.0% |
| Q3 2022 | $879,000 | +57.0% | 23,357 | +15.3% | 0.00% | 0.0% |
| Q2 2022 | $560,000 | -35.2% | 20,251 | +27.5% | 0.00% | 0.0% |
| Q1 2022 | $864,000 | +6.3% | 15,886 | +14.3% | 0.00% | 0.0% |
| Q4 2021 | $813,000 | +44.9% | 13,902 | -2.0% | 0.00% | 0.0% |
| Q3 2021 | $561,000 | -2.3% | 14,185 | +5.0% | 0.00% | 0.0% |
| Q2 2021 | $574,000 | -31.8% | 13,505 | -1.2% | 0.00% | 0.0% |
| Q1 2021 | $842,000 | -12.3% | 13,675 | +0.5% | 0.00% | 0.0% |
| Q4 2020 | $960,000 | +254.2% | 13,611 | +93.8% | 0.00% | – |
| Q3 2020 | $271,000 | -7.8% | 7,023 | -10.4% | 0.00% | – |
| Q2 2020 | $294,000 | – | 7,834 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,412,705 | $99,652,000 | 10.82% |
| CHI Advisors LLC | 433,852 | $30,604,000 | 8.62% |
| VR Adviser, LLC | 672,306 | $47,424,000 | 6.97% |
| Consonance Capital Management LP | 557,095 | $39,297,000 | 3.67% |
| Logos Global Management LP | 450,000 | $31,743,000 | 2.72% |
| RA Capital Management | 1,875,000 | $132,263,000 | 1.85% |
| Nantahala Capital Management | 534,514 | $37,705,000 | 1.17% |
| Orbimed Advisors | 1,679,417 | $118,466,000 | 1.04% |
| Eventide Asset Management | 346,000 | $24,407,000 | 0.37% |
| Atom Investors LP | 49,981 | $3,526,000 | 0.36% |